I Know First Reviews: May 25th, 2015

I Know First Reviews

The stocks selected here are the top performing stocks from I Know First: Daily Market Forecast’s May 24th, 2015 stock forecast titled “Best Biotech Stocks Based On Algorithm: Up To 98.04% In 14 Days”.

This forecast is part of the “Industry  Biotech Stocks” package, as one of I Know First’s quantitative investment solutions. The “I Know First Average” return was 15.77% over 3 months versus the S&P 500’s return of 1.38% over the same time period.

Review

Learn how to read the predictions: Instructions

Learn how to strategize with the forecast: Algorithmic Trading Strategies 

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

 

  Signal: 358.41OXGN

  Predictability: 0.2

  Return: 13.87%

OXiGENE is a clinical-stage, biopharmaceutical company developing therapeutics primarily to treat cancer. The company had a signal strength of 358.41 and a predictability indicator of 0.2. In accordance with the algorithm’s prediction, the stock price increased 13.87%. The company just announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of $10 million of registered shares of OXiGENE common stock in an at-the-market direct offering, at a price of $1.7125 per share.

 

  Signal: 222Review.95

  Predictability: 0.22

  Return: 9.21%

XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The company had a signal strength of 222.95 and a predictability indicator of 0.22. In accordance with the algorithm’s prediction, the stock price increased 9.21%. The CEO of the company, John Varian, just disclosed his insider activities with the SEC on the 19th of May. As discovered in the document, John had unloaded 10,000 shares of the company. Also its main product, the Gevokizumab, have reached several achievements in the medical world recently. These achievements are reassuring for the future.

 

exelixis-300

 Signal: 85.23

 Predictability: 0.32

 Return:  11.19%

 

Exelixis is a biopharmaceutical company which operates in the United States. Its main goal is to ameliorate the treatment of cancer developing small molecules therapies.  The company had a signal strength of 85.23 and a predictability indicator of 0.32. In accordance with the algorithm’s prediction, the stock price increased 11.19%. The company reported at the beginning of the month its first quarter earnings which were higher than expected. In fact, its first quarter revenue comes to $9.4 million whereas the estimation was $8.3 million.

 

medivation-logo Signal: 24.37

 Predictability: 0.34

 Return: 7.80%

Medivation is a biopharmaceutical company incorporated in 2000. They created innovative therapies which are efficient to threat serious diseases in the United States. The company had a signal strength of 24.37 and a predictability indicator of 0.34. In accordance with the algorithm’s prediction, the stock price increased 7.80%. Since 2009, Medivation and Astellas, a pharmaceutical company, collaborated on development studies which are focused on the utilization of the enzalutamide. They want to use the enzalutamide molecule as an innovative medicine. Few days ago, they announced that they have found new data on the enzalutamide which is an important step on their project, increasing then investor confidence.

 

48809_SareptaTherapeuticsSignal : 19.74

Predictability : 0.13

Return: 98.04%

Sarepta Therapeutics is a biopharmaceutical company which makes research and development. This firm mainly works on RNA-based therapeutics. The company had a signal strength of 19.74 and a predictability indicator of 0.13. In accordance with the algorithm’s prediction, the stock price increased 98.04%. This huge return can be explained by the creation of a new revolutionary medicine which can be able to threat the muscular dystrophy.  In fact, the stock soared more than 50% on Wednesday 20th, the day after their announcement about their muscular dystrophy drug.

 

Teva-Pharmaceutical-Industries

Signal: 19.31

Predictability: 0.39

Return: -0.16%

 

Teva company is a provider of pharmaceutical products worldwide. They are specialized in generic drugs. It headquarters is located in Petah Tikva in Israel. They started in Jerusalem in 1901 as a small wholesale drug firm distributing imported medicines. Now, this company is part of the 25 biggest pharmaceutical company in the world.

 

 

Sanofi.svg  Signal: 18.53

  Predictability: 0.47

  Return: 4.57%

 

Sanofi is a french pharmaceutical group which have its headquarter in Paris. Sanofi was created in 1973. Over time, severals fusions and acquisitions occurred, including Sterling Winthrop, Synthélabo and Aventis. In terms of revenues, Sanofi is the number 2 worldwide. The company had a signal strength of 18.53 and a predictability indicator of 0.47. In accordance with the algorithm’s prediction, the stock price increased 4.57%. Sanofi stock is down 8% over the past year due to the weak outlook of its diabetes business but the return has become higher thanks to the potential expansion with emerging market, especially in Asia.

roche-holding_416x416

 

 Signal: 17.85

 Predictability: 0.38

 Return: 3.62%

Roche is a pharmaceuticals and diagnostics company based in Switzerland. This company stays focus on a “personalized medicine”. It operates in 150 countries and reaches the top-1 of cancer medicines. The company had a signal strength of 17.85 and a predictability indicator of 0.38. In accordance with the algorithm’s prediction, the stock price increased 3.62%. We notice that Roche stock rallied after its positive trial results. In fact, Roche climbs 2.8 percent after reporting strong results from cancer drug trials

 

AMGNSignal: 16.51

Predictability: 0.42

Return: 3.35%

Amgen company produces and distributes drugs throughout the United States. The firm uses science and biotechnology to help people to restore health. The company had a signal strength of 16.51 and a predictability indicator of 0.42. In accordance with the algorithm’s prediction, the stock price increased 3.35%.  Amgen stock seems to be a great investment since the company has been recently ranked second among the top research companies.

 

BMY

 

 Signal: 16.02

 Predictability: 0.49

 Return: 6.23%

Bristol-Myers Squibb is an American pharmaceutical company created in 1989 after the fusion between Bristol-Myers Company and Squibb Corporation. Its mission is to overcome serious diseases manufacturing prescription pharmaceuticals. The company had a signal strength of 16.02 and a predictability indicator of 0.49. In accordance with the algorithm’s prediction, the stock price increased 6.23%. Bristol obtained the approval to distribute its Opdivo drugs. Also, the company will be able to distribute in additional geographies so the drug’s growth potential would increase.

 

Business Disclosure: I Know First Research is the analytic branch of I Know First, a financial startup company that specializes in quantitatively predicting the stock market. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Read More From I Know First Research:

  • Electric Buses Vs. Fuel Cell Buses: Plug Power Has A Stake In The Winner (View)
  • Why BlackBerry Holds Long-Term Value For Investors (View)
  • Tata Motors Is An Attractive Opportunity: An Algorithmic Analysis (View)
  • Applied Material’s Venture Group Invests Into UV LED, An Interesting Portfolio Expansion With Growth Potential (View)
  • Can Apollo Fight Online Education Any Longer? (View)